Japanese health officials say they are looking at new ways to help drug companies maintain prices on older, established medicines that are still effective but at risk of being supplanted by newer, more expensive compounds, according to a Japan News report.
India's ability to copy chemical-based drugs has been the foundation of the country's $15 billion pharmaceuticals industry, but its inability to produce more complex biological drugs at scale means regions like South Korea, the United States and Europe are already well ahead in the race, according to a report by the Economic Times.
China's State Council approved a plan this week submitted by the Jiangsu provincial government and the Ministry of Commerce for a pilot program in the China-Singapore Suzhou Industrial Park, which is already home to several pharmaceutical production plants and research facilities.
Despite the West Africa Ebola epidemic's tapering off, a Chinese firm says it will invest $315 million into a facility in Tianjin to mass produce an Ebola vaccine developed by a group out of China's Academy of Military Medical Sciences, Reuters
The Indian government may be upping the ante for drugmakers that fail to follow new guidelines by doubling the penalties it imposes when manufacturing plants attract the ire of international regulators, according to a report in the Hindustan Times.
Myanmar is trying to kick-start its pharmaceutical manufacturing industry, which currently consists of a handful of state-owned factories and one public-private joint venture, to wean itself off foreign imports, according to a recent report on the Frontier Myanmar news website.
Indian pharmaceutical firms got some good news last week when it was reported that during the period from July to September there was a 50% gain in the number of abbreviated new drug approvals (ANDAs) by the U.S. FDA, Bloomberg TV India reported.
Indian drug manufacturers are working to combine drugs used to treat hepatitis C in ways not possible in the West because of patent restrictions, according to a Bloomberg News report.
Dilip Shah, secretary-general of the Indian Pharmaceutical Alliance, said this week's decision by the Delhi High Court against homegrown Glenmark Pharmaceuticals showed "due process was followed" and that Indian companies could not count on Indian courts for special treatment, according to a report in the Wall Street Journal.
China oncology biotech BeiGene has snapped up Changzhen Wu to head a manufacturing operation that is in the process of outfitting a major facility in Suzhou, building on another key hire snatched from WuXi AppTec to build out a formidable team.